---
schema_version: "secwatch.filing_event.v1"
accession: "0001601830-23-000056"
form_type: "8-K"
ticker: "RXRX"
cik: "0001601830"
company_name: "RECURSION PHARMACEUTICALS, INC."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T02:02:47.870256+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Recursion predicts protein targets for 36B compounds; Q2 net loss $76.7M, revenue $11M

## Summary
- Predicted protein targets for ~36B compounds in Enamine REAL Space, evaluating 2.8 quadrillion target-compound pairs using NVIDIA DGX Cloud.
- Q2 2023 revenue $11.0M (up from $7.7M); net loss $76.7M (up from $65.6M); cash $405.9M, excluding $50M NVIDIA investment.
- Received $50M investment from NVIDIA; collaboration to build AI foundation models for drug discovery.
- Appointed David Mauro as CMO and Nathan Hatfield as Chief Legal Officer.
- First Phase 1 data readout for REC-3964 expected in Q3 2023; multiple pipeline catalysts through 2024-2025.

## SEC filing metadata
- accession: 0001601830-23-000056
- form_type: 8-K
- ticker: RXRX
- cik: 0001601830
- company_name: RECURSION PHARMACEUTICALS, INC.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601830/000160183023000056/0001601830-23-000056-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601830/000160183023000056/rxrx-20230808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601830-23-000056
- JSON: https://secwatch.observer/filing/0001601830-23-000056.json
- Plain text: https://secwatch.observer/filing/0001601830-23-000056.txt

## Key facts
- Earnings Releases
  RECURSION PHARMACEUTICALS, INC. reported financial results for second quarter ending June 30, 2023.
  - Period: second quarter ending June 30, 2023
  - Result: reported results
  source text: Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates and financial results for its second quarter ending June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1601830/000160183023000056/0001601830-23-000056-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.